Cervical cancer prevention, early screening and treatment

In our country, the incidence of cervical cancer is number one in the gynaecology, the “first killer” threatening the health of women, and the age at which the disease occurs is young and most patients are in the middle and late stages of their treatment. It is reported that the youngest cases of cervical cancer are only 16 years old, and the rejuvenation of cervical cancer reminds us of the need to focus more on the prevention and treatment of cervical cancer.The majority of married women who have given birth have cervix cervix, and many fear that cancer will change. Cervical palsy is mostly caused by inflammation, accompanied by an increase in white belts, which does not amount to cervical cancer. However, the patient is warned about cervical cancer if he/she has a co-habited vaginal bleeding, vaginal fluid, increased white belts, abdominal pain. Risk factors for cervical cancer include early marriage, early childbearing, multiple childbearing, smoking, multiple sexual partners, reduced immunity, genetic susceptibility and HPV infection. In my country, cervical cancer is mainly caused by the HPV virus, which is classified as high-risk and low-risk, depending on its carcinogenicity.Continuing HPV infections, such as HPV 16 and 18, are the main cause of cervical cancer. The HPV virus is transmitted mainly through sexual transmission, in addition to mother-to-child transmission, and can also be infected by close daily contact.How to prevent cervical cancer? A good way of life, mainly for the sake of self-preservation: sexual life after adulthood, condom use, the total number of sexual partners is inappropriate and healthy; a reasonable diet; physical exercise and improvement; optimism and increased immunity; vaccination against cervical cancer; periodic medical examinations to screen for cervical cancer.HPV vaccinations effectively prevent cervical cancer. The HPV vaccine currently on the market is available at a price of two, four and nine for cervix cancer. The double price HPV vaccine can effectively prevent HPV16, 18 and 70 per cent cervical cancer. The four-priced HPV vaccine is effective in preventing HPV6, HPV11, HPV16, HPV18, 84 per cent of cervical cancer and 90 per cent of genital accelerants, as well as other cancers around reproductive tracts, such as sharp wetting, anal cancer and male penis cancer. HPV 9 effective prevention of HPV6, HPV11, HPV16, HPV18, HPV31, HPV33, HPV45, HPV52, HPV58, 92.1 per cent of cervical cancer, 85 per cent of vaginal cancer, 80 per cent of cervical (pre-cancer) pathologies, 50 per cent of lower-grade cervical pathologies, and 90 per cent of genital acoustic acoustic acoustic (strength wet) cancer.As HPV vaccinations do not effectively address existing pre-cancer infections, such as HPV infections, genital thorium, and vaccines do not prevent all HPV sub-infections known to cause cervical cancer. Cervical cancer screening should therefore be carried out on a regular basis, whether or not HPV vaccinations have been administered. Screening for cervical cancer includes gynaecological examinations; HPV tests; and cervical cytology tests. Women currently recommended for screening for three years and above of their married or sexually active history: one in three years after three years of continuous cervical cytology screening at ages 1, 1 and 29; one in three years after three years of continuous cervical cytology at ages 2, 30-65; or one in three years after three years of continuous screening; or one in five years after three years of joint screening for high-risk HPV and cervical cytology; 3 at the end of the screening: >65 years after multiple examinations indicating negativeness; end of the screening; 20 years of continuous screening for women who have been diagnosed with a high-prevalence cystal disease (HSIL) and are screened at a frequency that is determined by the condition; 4, women who have undergone cervial hysteria (without neck) and who have not had CIN2, CIN3, original cancer or cancer in the past 20 years, do not need to be examined; 5 women who have received HPV vaccine and follow the recommendations of a specific age (like those who have not been vaccinated).Early cervical cancer is mainly surgically treated, i.e. IB1, IIB2, IIA1: surgery or treatment is used, and is expected to be good. The total 5-year survival rate for IB is about 80 ~90 per cent, of which cervical tumours are more than 4 cm in diameter, with a 5-year survival rate of only 40 ~70 per cent for persons with high-risk factors such as lymphocytes transfer, cervicinary oxidation and/or ectopositive; (2) IB3, IIA2: the treatment options are: 1 synchronised plasterization; 2 hysterectomy and pelvic lymphatic lymphatic lymic lymphosis, sampling of abdominal lymphoma, and post-automized assisted hysterectomy; 3 post-synthetic surgery; 4 synchronous hysterectomy. The above method is preferred to synchronize chemotherapy. (3) IIB ~ IVA: Synchronized chemotherapy; (4) IVB: support for treatment, mainly through system treatment, with some patients being able to combine local surgery or individualized treatment. Cervical cancer